Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
BOSTON – A new book telling the rough-and-tumble rise of China’s Sinovac Biotech (NASDAQ: SVA) will be published on February 1.
Sinovac plans to manufacture 1 billion doses of its COVID-19 vaccine, CoronaVac, this year, making it one of the top producers in the world.
The author, fund manager Peter Halesworth, has witnessed Sinovac’s rise to the forefront of the fight against COVID-19. Despite the ups and downs portrayed in the book, Sinovac is now seen as a major ally in the global fight against the pandemic. The company also displays China’s scientific prowess by supplying nations across three continents with CoronaVac.
Highlights of “Conquering COVID” include:
- How Sinovac’s experience in the early 2000s with SARS (Severe Acute Respiratory Syndrome) positioned it for its relative, COVID-19, today.
- How Sinovac, once ignored by Wall Street, is being transformed by COVID-19.
- How a battle for control of Sinovac has frozen the company’s value during an incredible bull run in COVID-19 vaccine stocks
A website for the book is available via this link: https://www.sinovacbook.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!